Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 19, Number 1—January 2013

Dispatch

Klebsiella pneumoniae Antimicrobial Drug Resistance, United States, 1998–2010

Guillermo V. Sanchez, Ronald N. Master, Richard B. Clark, Madiha Fyyaz, Padmaraj Duvvuri, Gupta Ekta, and Jose BordonComments to Author 
Author affiliations: Author affiliations: George Washington University, Washington, DC, USA (G.V. Sanchez); Quest Diagnostics Nichols Institute, Chantilly, Virginia, USA (R.N. Master, R.B. Clark); Providence Hospital, Washington (M. Fyyaz, P. Duvvuri, G. Ekta, J. Bordon)

Main Article

Table 2

Klebsiella pneumoniae antimicrobial drug resistance rates, United States, 2010*

Source, no. samples AMK GEN TOB TZP ATM IPM CAZ CRO CPM TMP/SXT CIP TET
All, 187,359 4.5 9.2 13.8 12.7 22.2 4.3 17.2 12.1 7.7 19.3 16.8 16.7
Blood, 20,185 4.2 10.6 14.9 15 23.6 5.9 19.2 13.4 7.1 21.3 18.9 17.1
Urine, 112,567 4.1 7.8 12.4 10.6 21 3.8 15.1 10.9 7.1 18.3 15.1 17.3
Wound, 22,225 4.5 10.1 14.4 14.7 20.9 5 17.5 12.2 8.3 19.5 16.8 16.4
Respiratory, 32,382 5.8 11.1 15.8 16.4 24.5 4.7 21.3 15.5 9.9 20.2 20 15.5

*AMK, amikacin; GEN, gentamicin; TOB, tobramycin; TZP, piperacillin/tazobactam; ATM, aztreonam; IPM, imipenem; CAZ, ceftazidime; CRO, ceftriaxone; CPM, cefepime; TMP/SXT, trimethoprim/sulfamethoxazole; CIP, ciprofloxacin; TET, tetracycline.

Main Article

TOP